A group of scientists, medical professionals, and researchers led by Battelle and The Ohio State University Wexner Medical Centre have shown for the first time that a person with a clinically complete spinal cord injury (SCI) can use a brain-computer interface (BCI) to simultaneously reanimate both motor function and sense of touch to improve quality of life and assist individuals in being more entire once again and less reliant on caregivers.
A team of Johns Hopkins neurosurgeons and biomedical engineers developed implantable ultrasound technology and other devices to completely change the way spinal cord injury patients are treated and to assist medical professionals in observing and managing the changes in blood flow and avoiding tissue death that happens right away after a spinal cord accident.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 3951
Published Date: Jan 12, 2024
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The increasing incidence of spinal cord injuries across the world and the growing advancement in the field of quadriplegia treatment are the major factors driving the growth of the market.
The market size of quadriplegia treatment is anticipated to attain a CAGR of 5% over the forecast period, i.e., 2024-2036.
The major players in the market are Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Bristol Myers Squibb Company, and others.
The hospital pharmacies segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.